Nrf2 activators and inhibitors have demonstrated significant potential in clinical trials across multiple disease areas (e.g., neurodegenerative diseases, chronic kidney disease, cancer), though their specific indications and safety profiles require further investigation and validation. This evidence concerns the gene NFE2L2 and cancer.